Sunesis to Host Conference Call on November 5th to Discuss Third Quarter 2015 Financial Results and Recent Highlights
Get Alerts SNSS Hot Sheet
Join SI Premium – FREE
SOUTH SAN FRANCISCO, Calif., Oct. 29, 2015 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (NASDAQ: SNSS) today announced that it will host a conference call on Thursday, November 5, 2015 at 11:00 a.m. Eastern Time to discuss corporate updates and financial results for the third quarter ended September 30, 2015.
The call can be accessed by dialing (877) 771-6242 (U.S. and Canada) or (440) 996-5676 (international), and entering passcode 66013619.
To access the live audio webcast, or the subsequent archived recording, visit the "Investors and Media - Calendar of Events" section of the Sunesis website at www.sunesis.com. The webcast will be recorded and available for replay on the company's website for two weeks.
About Sunesis Pharmaceuticals
Sunesis is a biopharmaceutical company focused on the development and commercialization of new oncology therapeutics for the potential treatment of solid and hematologic cancers. Sunesis has built a highly experienced cancer drug development organization committed to advancing its lead product candidate, vosaroxin, in multiple indications to improve the lives of people with cancer.
For additional information on Sunesis, please visit http://www.sunesis.com.
SUNESIS and the logos are trademarks of Sunesis Pharmaceuticals, Inc.
CONTACT: Investor and Media Inquiries: David Pitts Argot Partners 212-600-1902 Eric Bjerkholt Sunesis Pharmaceuticals, Inc. 650-266-3717Source: Sunesis Pharmaceuticals, Inc.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- American Airlines (AAL) Misses Q1 EPS by 7c, Guidance Beats
- Sonic Automotive (SAH) Tops Q1 EPS by 4c
- MarineMax (HZO) Misses Q2 EPS by 48c, provides guidance
Create E-mail Alert Related Categories
Press ReleasesRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!